Transgene SA (TNG.PA)

1,3440 +0,0240 (+1,82%) Börsenschluss: 05:35PM CEST

Transgene SA

400, boulevard Gonthier d’Andernach
Parc d’innovation CS80166 Cedex
Illkirch-Graffenstaden 67405
France
33 3 88 27 91 00
https://www.transgene.fr

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 141

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Alessandro Riva M.D.	CEO & Chairman of the Board	67k	N/A	1961
Ms. Lucie Larguier	Chief Financial Officer	N/A	N/A	N/A
Dr. Eric Quemeneur Ph.D., Pharm.D.	Executive VP & Chief Scientific Officer	N/A	N/A	1965
Mr. John Felitti J.D., LLM	VP, General Counsel & Corporate Secretary	N/A	N/A	1970
Ms. Christelle Schwoerer	Chief Human Resources Officer	N/A	N/A	N/A
Dr. Maud Brandely-Talbot M.D., Ph.D.	VP of Medical Affairs & Chief Medical Officer	N/A	N/A	1954
Mr. James Wentworth M.B.A., Ph.D.	VP & Chief Business Officer	N/A	N/A	N/A
Ms. Gaelle Stadtler	VP & Director of Human Resources	N/A	N/A	1984
Kaidre Bendjama	Project Leader of Personalized Cancer Vaccines	N/A	N/A	N/A
Ms. Elisabetta Castelli Ph.D.	Director of Investor Relations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Corporate Governance

Transgene SAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.